News & Updates

Show Multimedia Only

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

06 Apr 2026

In adult patients with diabetes and epilepsy, treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with lower risks of seizure recurrence, hospitalization, and mortality compared with other glucose-lowering therapies, according to a retrospective study.

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

06 Apr 2026

Adagrasib shows promise in treatment of mutated solid tumours

05 Apr 2026

Treatment with the selective KRAS G12C inhibitor adagrasib significantly improves survival and yields high response rates in patients with KRAS G12C-mutant solid tumours, a study has shown.

Adagrasib shows promise in treatment of mutated solid tumours

05 Apr 2026

ASM use may be stopped right after resolution of acute provoked neonatal seizures

04 Apr 2026

In neonates with acute provoked seizures, continued use of antiseizure medications (ASMs) even after resolution of seizures may be unnecessary, as shown in a prospective, comparative effectiveness study.

ASM use may be stopped right after resolution of acute provoked neonatal seizures

04 Apr 2026

Hormone therapy augments weight-loss response with tirzepatide in postmenopausal women

03 Apr 2026 by

In postmenopausal women receiving treatment with tirzepatide for overweight or obesity, concurrent use of hormone therapy confers greater reduction in weight as well as improvement in cardiometabolic outcomes, according to a retrospective cohort study.

Hormone therapy augments weight-loss response with tirzepatide in postmenopausal women

03 Apr 2026

Durvalumab plus olaparib extends PFS in non-BRCA-mutated advanced ovarian cancer

03 Apr 2026 by

First-line durvalumab plus carboplatin/paclitaxel and bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance significantly improves progression-free survival (PFS) in patients with newly diagnosed non-BRCA-mutated advanced ovarian cancer, when compared with carboplatin/paclitaxel and bevacizumab followed by bevacizumab, as shown in the DUO-O study.

Durvalumab plus olaparib extends PFS in non-BRCA-mutated advanced ovarian cancer

03 Apr 2026

Novel tyrosine kinase 2 inhibitor looks good for AD

03 Apr 2026

In the treatment of patients with atopic dermatitis, the investigational tyrosine kinase 2 inhibitor ICP-332 demonstrates a favourable safety profile with promising efficacy, according to a phase II study.

Novel tyrosine kinase 2 inhibitor looks good for AD

03 Apr 2026

Many HFrEF patients not receiving optimal GDMT

02 Apr 2026 by

The uptake and optimization of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF) remain poor in Singapore, owing to underprescription, inadequate dosing, and medication discontinuation, according to a retrospective study.

Many HFrEF patients not receiving optimal GDMT

02 Apr 2026

Imlunestrant improves survival, delays chemo in advanced breast cancer

02 Apr 2026 by

Imlunestrant-based regimens provide clinically meaningful improvements in progression-free survival (PFS), as well as overall survival (OS), in endocrine-pretreated patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC), results of the phase III EMBER-3 trial have shown.

Imlunestrant improves survival, delays chemo in advanced breast cancer

02 Apr 2026

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

02 Apr 2026

In the treatment of patients with juvenile localized scleroderma, mycophenolate mofetil compares favourably with methotrexate in terms of reducing clinical activity and flare rate, according to a retrospective study.

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

02 Apr 2026

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

01 Apr 2026 by

The highly selective colony-stimulating factor-1 receptor inhibitor pimicotinib demonstrates robust antitumour activity in patients with tenosynovial giant cell tumour, yielding meaningful improvements in physical function and symptom burden with a manageable safety profile, according to the international phase III MANEUVER trial.

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

01 Apr 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

GLP-1RA linked to reduced seizure recurrence risk in diabetic adults with epilepsy

Adagrasib shows promise in treatment of mutated solid tumours

Adagrasib shows promise in treatment of mutated solid tumours

ASM use may be stopped right after resolution of acute provoked neonatal seizures

ASM use may be stopped right after resolution of acute provoked neonatal seizures

Hormone therapy augments weight-loss response with tirzepatide in postmenopausal women

Hormone therapy augments weight-loss response with tirzepatide in postmenopausal women

Durvalumab plus olaparib extends PFS in non-BRCA-mutated advanced ovarian cancer

Durvalumab plus olaparib extends PFS in non-BRCA-mutated advanced ovarian cancer

Novel tyrosine kinase 2 inhibitor looks good for AD

Novel tyrosine kinase 2 inhibitor looks good for AD

Many HFrEF patients not receiving optimal GDMT

Many HFrEF patients not receiving optimal GDMT

Imlunestrant improves survival, delays chemo in advanced breast cancer

Imlunestrant improves survival, delays chemo in advanced breast cancer

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial

Pimicotinib for tenosynovial giant cell tumour hits targets in pivotal trial